Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
Aging, the gradual decline of physiological functions over time, is becoming a major focus in drug development due to its growing global significance. By 2050, the UN Department of Economic and Social Affairs estimates that over two billion people will be aged 60 and above, making up more than a quarter of the world’s population. According to the aging pipeline analysis by Expert Market Research, current therapies target age-associated conditions, including neurodegenerative, cardiovascular, and metabolic disorders, with innovations such as senolytics, NAD+ enhancers, and regenerative treatments. Increased research funding, technological progress, and rising demand for healthy longevity are expected to drive strong growth in the pipeline over the coming years.
-
Major companies involved in the aging pipeline analysis include Biophytis, PRG Science & Technology Co., Ltd., and others.
-
Leading drugs currently in the pipeline include BIO101, Progerinin, and others.
-
The Aging drug sector is poised for significant expansion, driven by increasing prevalence of age-related disorders, rising investment in regenerative therapies, and growing focus on senolytic and cellular rejuvenation treatments.
Report Coverage
The Aging Pipeline Analysis Report by Expert Market Research gives comprehensive insights into aging therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Aging. The aging report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The aging pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with aging treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to aging.
Read more about this report - Request a Free Sample
Aging Pipeline Outlook
Aging is a progressive biological process marked by the gradual decline of cellular, tissue, and organ function over time. It occurs due to cumulative molecular damage, genomic instability, telomere shortening, mitochondrial dysfunction, and altered cellular signaling, ultimately reducing physiological resilience and increasing vulnerability to chronic diseases.
The aging treatments are managed through lifestyle interventions, pharmacological agents, and regenerative approaches targeting inflammation, cellular senescence, and metabolic dysfunction, with emerging therapies focusing on stem cells, gene modulation, and disease-modifying drug candidates. In July 2025, Longeveron Inc. announced United States Food and Drug Administration approval of its Investigational New Drug application for laromestrocel, an allogeneic mesenchymal stem cell therapy, enabling advancement into a Phase 2 pivotal clinical trial targeting Aging-related regenerative and cardiovascular conditions.
Aging Epidemiology
Aging Drug Pipeline Analysis highlights epidemiological trends driven by a rapidly expanding elderly population. According to the United Nations Department of Economic and Social Affairs, the global population aged 60 years and above is projected to reach 2.1 billion by 2050, compared with 1.2 billion in 2024. As per the United States Census Bureau, 61.2 million people aged 65 and over lived in the United States in 2024. According to the World Health Organization, Europe’s population aged 60 and older will exceed 300 million by 2050. As per the Press Information Bureau, India’s senior population may reach 230 million by 2036.
Aging – Pipeline Therapeutic Assessment
This section of the report covers the analysis of aging drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
The aging pipeline analysis report covers 50+ drug analyses based on drug classes:
- Small Molecules
- Monoclonal Antibodies
- Gene Therapies
- Peptides
- Vaccine
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration:
- Oral
- Parenteral
- Others
Aging Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total aging clinical trials, accounts for 41%, representing the largest share of the aging market drug pipeline, and highlighting strong mid-stage clinical momentum. Phase IV contributes 17%, reflecting growing post-marketing research. This trend indicates increasing real-world evidence generation and supports validation of long-term safety and effectiveness in aging-related therapies.
Aging Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the aging pipeline analysis include small molecules, monoclonal antibodies, gene therapies, peptides, and vaccines. The aging report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for aging. Target of Rapamycin pathway inhibitors represent an emerging drug class in the aging market drug pipeline. For instance, Rapalink-1, a next-generation small-molecule inhibitor of the Target of Rapamycin inhibitor, is under investigation for its lifespan-extending potential. It modulates Target of Rapamycin Complex 1 activity, slows cellular growth, and supports healthy aging mechanisms linked to metabolic regulation.
Aging Clinical Trials – Key Players
The EMR report for the Aging pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed Aging therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in Aging clinical trials:
- Biophytis
- PRG Science & Technology Co., Ltd.
- Longeveron Inc.
- SIPO Biotechnology Co. Ltd.
- Acorn Biolabs Inc.
- Life Biosciences Inc.
- Bio-Medical Research, Ltd.
- RDC Clinical Pty Ltd.
- Bio-Gen Extracts Pvt. Ltd.
- Stealth BioTherapeutics Inc.
- GlaxoSmithKline
- Galderma R&D
Aging – Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for aging. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of Aging drug candidates.
Drug: BIO101
BIO101 is being developed by Biophytis as a first-in-class oral small-molecule therapy for age-related sarcopenia, targeting muscle weakness and functional decline in older adults. The Phase 3 SARA trial is being sponsored by Biophytis and is examining the efficacy, safety, and functional benefits of BIO101 in 932 sarcopenic patients across Europe, China, and Japan. BIO101 is modulating mitochondrial and muscle metabolism pathways to improve muscle strength and mobility. The study aims to establish BIO101 as a potential disease-modifying treatment in a high-unmet-need Aging population.
Drug: Progerinin
Progerinin is an investigational small-molecule therapy sponsored by PRG Science & Technology Co., Ltd., with research funding support from The Progeria Research Foundation. The Phase 2a clinical study is evaluating the safety, tolerability, and pharmacodynamic effects of Progerinin in combination with Zokinvy in patients with Progeria. The drug targets toxic progerin accumulation by reducing intracellular progerin levels, thereby mitigating cellular damage. Progerinin is being administered orally and aims to improve cardiovascular outcomes and disease progression in this ultra-rare aging disorder.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
Key Questions Answered in the Aging Pipeline Insight Report
- Which companies/institutions are leading the aging drug development?
- Which company is leading the aging pipeline development activities?
- What is the current aging commercial assessment?
- What are the opportunities and challenges present in the aging pipeline landscape?
- What is the efficacy and safety profile of the aging pipeline drugs?
- Which company is conducting major trials for aging drugs?
- Which companies/institutions are involved in aging collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in aging?
Reasons To Buy This Report
The Aging Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for Aging. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into aging collaborations, regulatory environments, and potential growth opportunities.
Related Reports
Pricing Plans
Upto 15% Off
USD
-
$1999 $1799
-
$3099 $2789
-
$4599 $3909
-
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Looking for specific insights?
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share